secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kronos Bio, Inc. (—)
CIK:        0001741830
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0001741830-24-000036
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kronos Bio Q1 net loss $30M, cash $152M into H2 2026; restructuring charges $12.8M
--------------------------------------------------------------------------------

- Net loss of $30.0M ($0.50/share) includes $7.7M stock-based comp; R&D $14.2M, G&A $7.5M.
- Impairment of long-lived assets $6.6M; restructuring expense $6.2M (includes $4.4M stock-based comp).
- Cash, equivalents and investments $152.0M, sufficient into second half of 2026.
- KB-0742 Phase 1/2 update to be presented at ASCO June 1; expansion cohorts on track Q3 2024.
- KB-9558 IND-enabling studies to complete by end 2024; first-in-human expected H1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1741830/000174183024000036/0001741830-24-000036-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1741830/000174183024000036/kron-20240509.htm
  HTML page:      https://secwatch.observer/filing/0001741830-24-000036

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer